ProductsIntelligenceLicensingAnalyst AccessPricingMethodologyContact
HEALTHCARE & LIFE SCIENCES

Controlled Unclassified Information handling

Healthcare and life sciences organizations handling Controlled Unclassified Information face a tightening compliance posture driven by the U.S. Department of Defense's CMMC 2.0 framework and active enforcement attention from the U.S. Department of Health and Human Services Office for Civil Rights, both of which assert overlapping authority when federal contracts and patient data intersect. The National Institute of Standards and Technology SP 800-171 revision 3, finalized in mid-2024, raised the baseline controls that defense-adjacent health contractors must meet, and compliance teams are now mapping vendor agreements and data-handling workflows against the updated requirement set before contract renewal cycles hit. CUI obligations in this sector are not theoretical: hospitals, CROs, and medical device manufacturers holding federal contracts are active targets.

Watch

  • CMMC 2.0 Level 2 certification deadlines for healthcare contractors with DoD agreements
  • NIST SP 800-171 Rev. 3 gap assessments due before new federal contract awards
  • HHS OCR's position on CUI overlap with Protected Health Information in dual-use systems
  • National Archives and Records Administration CUI Registry updates affecting clinical research categories
  • False Claims Act exposure tied to self-attestation of CMMC compliance in healthcare primes

Recent material activity in Healthcare & Life Sciences

A selection of recent published briefs; this is not a complete archive.

  • Sep 24, 2026MATERIAL

    FDA issues warning letter and import alert to Indian contract drug manufacturer for records access refusal

    FDA's Center for Drug Evaluation and Research issued a warning letter on February 13, 2025, to Zenzi Pharmaceutical Industries Pvt. Ltd. in Maharashtra, India, for refusing to provide records under the foreign records ac…

    Read a full sample brief →
  • Sep 24, 2026MATERIAL

    FDA closes warning letter against Zenzi Pharmaceutical but maintains Import Alert 66-79 over inspection refusal

    FDA's Center for Drug Evaluation and Research issued a closeout letter on September 18, 2026 to Zenzi Pharmaceutical Industries Private Limited, a Maharashtra-based drug manufacturer. The firm remains on Import Alert 66-…

    Read a full sample brief →
  • Sep 24, 2026MATERIAL

    FDA approves belzutifan plus lenvatinib combination for advanced clear cell renal cell carcinoma in adults

    The FDA approved belzutifan combined with lenvatinib on September 24, 2026, for adults with advanced renal cell carcinoma with a clear cell component. This expands the labeled indications for both agents. The approval es…

    Read a full sample brief →
  • Sep 24, 2026MATERIAL

    Health Canada safety alert flags premature battery drain in Stryker Inzone Detachment System affecting coil delivery function

    Health Canada published a safety alert on September 24, 2026 covering Stryker's Inzone Detachment System following observations of premature battery drain. Affected devices may fail to power on, present diminished indica…

    Read a full sample brief →
  • Sep 24, 2026MATERIAL

    FDA Class I recall removes all Abiomed Automated Impella Controllers over purge flag failures linked to 37 injuries and three deaths

    The FDA has classified Abiomed's removal of all Automated Impella Controllers as a Class I recall — its most serious designation — following purge flag component failures within the purge pressure sensor assembly. As of …

    Read a full sample brief →
  • Sep 24, 2026MATERIAL

    FDA Class I recall removes all Automated Impella Controllers globally over purge flag failures linked to 37 injuries and three deaths

    The FDA has classified Abiomed's removal of all Automated Impella Controllers as a Class I recall — its most serious designation — following purge flag component failures within the purge pressure sensor assembly. As of …

    Read a full sample brief →
  • Sep 24, 2026MATERIAL

    FDA classifies BD convenience kit correction as Class I recall over recalled sodium chloride ampules

    The FDA on September 24, 2026 elevated its August 18 Early Alert for Becton Dickinson convenience kits and procedure trays to a Class I recall classification. The kits contain sodium chloride ampules subject to a prior H…

    Read a full sample brief →
  • Sep 24, 2026MATERIAL

    FDA classifies Becton Dickinson convenience kit correction as Class I recall over sterility-compromised sodium chloride ampules

    The FDA on September 24, 2026 elevated its August 18 Early Alert for Becton Dickinson convenience kits and procedure trays to a Class I recall classification. The affected kits contain sodium chloride ampules manufacture…

    Read a full sample brief →
  • Sep 24, 2026MATERIAL

    Health Canada Drugs & Medical Devices release pending Cresthaven Analytics full analysis: InterStim™ Systems

    Health Canada Drugs & Medical Devices published a regulatory release titled 'InterStim™ Systems'. Cresthaven Analytics' full intelligence brief is pending re-analysis; see the source link below for the complete primary t…

    Read a full sample brief →
  • Sep 24, 2026MATERIAL

    Baxter issues urgent correction for Likorall ceiling-mounted patient lift systems over double-fault drop risk

    Baxter Corporation issued an urgent correction on September 24, 2026 for the Likorall ceiling-mounted patient lift system. The correction targets a double-fault failure scenario in which simultaneous motor shaft breakage…

    Read a full sample brief →